COMMUNIQUÉS West-GlobeNewswire

Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
09/12/2025
Expert panel offers data-driven guidance for integrating DecisionDx-Melanoma into clinical decision-making for patients with melanoma FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. ( [...]
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
09/12/2025
Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP [...]
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
09/12/2025
Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 2025 1 , and core [...]
ONL Therapeutics Announces Publication of Data from Phase 1b Study of Xelafaslatide, an Investigational Therapy for Geographic Atrophy, in Ophthalmology Science
09/12/2025
Xelafaslatide was safe and well tolerated at all evaluated doses, with the potential to reduce GA lesion growth and improve vision ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical- [...]
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
09/12/2025
Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis 1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS) in MBC across all [...]
Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206, a biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada
09/12/2025
Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a strong foundation for a successful launch of FYB206 Strong early partnering interest [...]
Cronos to enter the Netherlands with acquisition of Europe’s largest adult-use cannabis company
09/12/2025
Cronos to acquire CanAdelaar for up-front cash consideration of US$67.0M 1 plus cash earnout of 0.5x normalized EBITDA in 2026 and 2027 Up-front consideration represents approximately 1.4x CanAdelaar LTM revenue and 2. [...]
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout
09/12/2025
Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Enrollment exceeding expectations with strong clinical site and patient interest Topline [...]
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
09/12/2025
HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform [...]
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
09/12/2025
Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag 1 ,2 62% of patients treated with ianalumab plus [...]
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
09/12/2025
New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s PRINCETON, N.J., Dec. 09 [...]
23andMe Research Institute Appoints John McLeod General Counsel and Chief Risk Officer
09/12/2025
PALO ALTO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- 23andMe Research Institute, a nonprofit medical research organization, today announced the appointment of John McLeod to the role of General Counsel and Chief Risk [...]
ORYZON Presents Data for Iadademstat Combinations in AML at the American Society of Hematology (ASH) 67th Annual Meeting
09/12/2025
100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients 80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 months and good [...]
AnswersNow Expands Virtual Autism Therapy and Caregiver Training Services to Colorado
09/12/2025
Leading provider of virtual ABA therapy offers personalized 1:1 therapy sessions with BCBAs within days from the comforts of home RICHMOND, Va., Dec. 09, 2025 (GLOBE NEWSWIRE) -- AnswersNow , the leader in virtual [...]
Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution
09/12/2025
Novel technology paves the way for use of the company's industry-leading point-of-care electroencephalography (EEG) system to address long unmet need in delirium monitoring SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE [...]
AskBio’s AB-1005 and AB-1002 Receive Pioneering Regenerative Medical Product Designation in Japan
09/12/2025
Berlin, Germany, and Research Triangle Park, N.C., USA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Not intended for UK Media Product designation supports development of innovative investigational gene therapies for Parkinson’s [...]
Codetta Bio™ Expands Global Commercial Leadership to Accelerate Worldwide Adoption of the Concerto™ System
09/12/2025
DURHAM, N.C., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Codetta Bio™, a leading innovator in multi-omic solutions that integrate ultrasensitive protein quantitation with simultaneous analysis of nucleic acids (RNA and DNA), [...]
LB Pharmaceuticals Added to the Russell 2000® and Russell 3000® Indices
09/12/2025
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the Company has been included in the Russell 2000 ® Index and the broad-market [...]

Pages